Skip to main content
NOVAVAX INC logo

NOVAVAX INC — Investor Relations & Filings

Ticker · NVAX ISIN · US6700024010 LEI · 529900J4GJHPEPQ23205 US Manufacturing
Open in API
Filings indexed 1,095 across all filing types
Latest filing 2021-03-17 Director's Dealing
Country US United States of America
Listing US NVAX

About NOVAVAX INC

https://www.novavax.com/?locale=US

Novavax Inc. is a biotechnology company that develops and commercializes vaccines to prevent serious infectious diseases. The company utilizes a proprietary, protein-based vaccine technology platform, which includes its novel Matrix-M™ adjuvant, to create its vaccine candidates. Its primary commercial product is a protein-based COVID-19 vaccine, Nuvaxovid™. Novavax's research and development pipeline is focused on addressing significant health needs, including influenza and a combination COVID-19-influenza vaccine. The company's strategy emphasizes advancing its pipeline assets and establishing strategic partnerships to maximize the global health impact of its technology.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2021-03-17 English
FORM 4 SUBMISSION
Director's Dealing
2021-03-09 English
FORM 4 SUBMISSION
Director's Dealing
2021-03-02 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report pursuant to the Securities Exchange Act of 1934. It reports on a material definitive agreement entered into by Novavax, Inc. with Takeda Pharmaceutical Company Limited regarding a collaboration and exclusive license agreement for a vaccine product. It also includes a press release about the company's financial results for the quarter and fiscal year ended December 31, 2020, attached as an exhibit. The document is not a full financial report like an Annual Report (10-K) or Interim Report (IR), nor is it a simple announcement of a report publication. It is a regulatory filing reporting material events and includes a financial results press release. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2021-03-02 English
10-K
Annual Report FY 2020
2021-03-01 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report pursuant to the Securities Exchange Act of 1934. It reports the entry into a material definitive agreement between Novavax, Inc. and SK bioscience regarding a collaboration and license agreement for a COVID-19 vaccine. The document includes detailed description of the agreement terms, parties involved, and regulatory responsibilities. It is not an annual or quarterly report, earnings release, or management discussion. It is a specific event-driven filing reporting a material contract, which is typical for Form 8-K filings. Therefore, the document fits best under the category of Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2021-02-19 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.